Johannes V. van Thienen

Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma

Christian U. Blank, Elisa A. Rozeman, Lorenzo F. Fanchi et al. · Nature Medicine · 2018 · 855 citations

Medicine, Immunology, Oncology +14

Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma

Maartje W. Rohaan, Troels Holz Borch, Joost H. van den Berg et al. · New England Journal of Medicine · 2022 · 536 citations · Full text

Medicine, Immunology, Oncology +17

Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial

Elisa A. Rozeman, Alexander M. Menzies, Alexander C. J. van Akkooi et al. · The Lancet Oncology · 2019 · 522 citations

Pharmacy, Oncology, Pharmacokinetics +16

Comparison of Immediate vs Deferred Cytoreductive Nephrectomy in Patients With Synchronous Metastatic Renal Cell Carcinoma Receiving Sunitinib

Axel Bex, Peter F.A. Mulders, Michael A.S. Jewett et al. · JAMA Oncology · 2018 · 490 citations · Full text

Medicine, Oncology, Surgery +17

Endothelial KLF2 Links Local Arterial Shear Stress Levels to the Expression of Vascular Tone-Regulating Genes

Rob J. Dekker, Johannes V. van Thienen, Jakub Rohlena et al. · American Journal Of Pathology · 2005 · 355 citations · Full text

Life Sciences, Molecular Biology, Physiology +12